A phase II study of Bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: A cytokine Working Group (CWG) study

Uday B. Dandamudi, Musie Ghebremichael, Jeffrey A. Sosman, Joseph I. Clark, David F. McDermott, Michael B. Atkins, Janice P. Dutcher, Walter J. Urba, Meredith M. Regan, Igor Puzanov, Todd S. Crocenzi, Brendan D. Curti, Ulka N. Vaishampayan, Nancy A. Crosby, Kim A. Margolin, Marc S. Ernstoff*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of Bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: A cytokine Working Group (CWG) study'. Together they form a unique fingerprint.

Medicine & Life Sciences